论文部分内容阅读
Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or
【作 者】
:
【机 构】
:
Memorial Sloan Kettering Cancer Center, New York, NY
【出 处】
:
2015年临床肿瘤学新进展学术研讨会
【发表日期】
:
2015年3期
其他文献
会议
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (p
会议
GADOLIN: Primary results from a phase Ⅲ study of obinutuzumab plus bendamustine compared with bendam
会议
Phase Ⅱ study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or doubl
会议
ELOQUENT-2: A phase Ⅲ, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/w
会议
Phase Ⅱa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patie
会议